Shares of Hera Med (ASX:HMD) have seen a significant rise of as much as 15% to A$0.023, marking their largest intraday percentage gain since December 18, 2023.
This lift of stock also puts the company at its highest level since February 28.
The spike in stock comes following the company’s recent strategic partnership agreement with FemBridge, a U.S.-based maternal solutions organization.
The aim of this agreement is to develop a scalable maternal health solution.
‘We anticipate achieving commercial milestones in the immediate future, with a steady growth trajectory expected throughout the remainder of 2024,’ say co-founders Traci Quillen and Maggie Huether.
The company has also seen a rise in trading volume, with about 911,410 shares changing hands, versus the 30-day average volume of 258,305 shares.
Despite the recent rise, the company’s stock is down 0.9% so far this year, as of the last close.
Hera Med (ASX:HMD) is a provider of pregnancy monitoring solutions.